Aurobindo Pharma Limited has informed the Exchange about completion Phase 3 Clinical Study for Denosumab Biosimilar vy CuaTeQ Biologics
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has announced the completion of the Phase 3 clinical study for its Denosumab biosimilar, developed through its biologics arm CuraTeQ Biologics. Denosumab is used in the treatment of osteoporosis and bone-related conditions, and the biosimilar market for this drug holds significant global potential. Completing Phase 3 is a major step toward seeking regulatory approvals in markets such as the US, Europe, and India. This progress strengthens Aurobindo's biologics pipeline, which is a key growth area for the company beyond its traditional small-molecule generics business.
This is a positive development for long-term growth but does not yet translate into immediate revenue, as commercial launch will depend on subsequent regulatory approvals. The stock may see a modest positive reaction, with the real upside likely to materialize closer to product approval and launch.